DelMar Pharmaceuticals, Inc. 4
4 · DelMar Pharmaceuticals, Inc. · Filed May 3, 2016
Insider Transaction Report
Form 4
Mohr Erich
Director
Transactions
- Purchase
Series B Preferred Stock
2016-04-29$8.00/sh+9,375$75,000→ 9,375 totalFrom: 2016-04-29→ Common Stock (93,750 underlying)
Footnotes (3)
- [F1]The Series B Preferred stock is convertible into such number of shares of common stock equal to the number of Preferred Shares to be converted, multiplied by the Stated Value of $8.00, divided by the Conversion Price in effect at the time of the conversion (the initial Conversion Price will be $0.80, subject to adjustment in the event of stock splits, stock dividends, and similar transactions).
- [F2]The Reporting Person purchased Series B Preferred Stock from the Company in a private placement on April 29, 2016 (the "Private Placement").
- [F3]The Series B Preferred Stock will automatically convert to common stock at the earlier of (a) the Company's lead product candidate, VAL-083, receiving Food and Drug Administration or European Medicines Agency approval (provided that, at the time of such approval, the closing bid price of the common stock is at least $2.00 (subject to adjustment for stock splits or stock dividends) or (b) five years from the final closing of the Private Placement.